Comparison of the efficacy of latanoprost versus dorzolamide/timolol fixed combination therapy in patients with pseudoexfoliative glaucoma according to glaucoma stage

被引:0
作者
Sultan, Pinar [1 ]
Gungel, Hulya [1 ]
Ciftci, Furkan [2 ]
机构
[1] Univ Hlth Sci, Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkiye
[2] Sanliurfa Training & Res Hosp, Dept Ophthalmol, Sanliurfa, Turkiye
关键词
Dorzolamide; Timolol; Glaucoma; Pseudoexfoliative glaucoma; Intraocular pressure; Latanoprost; Pharmaceutical preparations; TIMOLOL MALEATE 0.5-PERCENT; INTRAOCULAR-PRESSURE; BIMATOPROST; PROGRESSION; TRAVOPROST; MANAGEMENT; SAFETY; RISK; EYES;
D O I
10.5935/0004-2749.2021-0230
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Only a few trials have compared the intraocular pressure-lowering effects of prostaglandin analogs to carbonic anhydrase inhibitor plus beta-blocker fixed-dose combination therapy in patients with pseudoexfoliative glaucoma. Furthermore, the influence of the glaucoma stage on the intraocular pressure-lowering effects of these drug types has not been studied. The purpose of this study was to compare the IOP-lowering efficacy of latanoprost, a prostaglandin analog versus dorzolamide/ timolol fixed combination, a carbonic anhydrase inhibitor plus beta-blocker fixed-dose combination therapy, in patients with pseudoexfoliative glaucoma based on glaucoma stage. Methods: The data of 32 eyes (32 patients) diagnosed with uniocular pseudoexfoliative glaucoma and treated with topical latanoprost (Group 1) or dorzolamide/timolol fixed combination (Group 2) were retrospectively assessed. The groups were subdivided into early and moderate-advanced stages. Patients' demographics, baseline intraocular pressure, final intraocular pressure, and intraocular pressure difference (the difference between the baseline and final intraocular pressure) were determined from medical records and compared between groups and according to glaucoma stage. Results: The mean drug use duration was 17.7 +/- 13.5 months. No significant differences in mean baseline intraocular pressure, mean final intraocular pressure and mean intraocular pressure difference between Groups 1 and 2. In Group 2, the mean intraocular pressure difference was signifi-cantly greater in patients with early versus moderate-advanced stage glaucoma (p=0.015). The difference, however, was not detected in Group 1. The mean intraocular pressure difference in early-stage glaucoma was significantly greater in Group 2 versus 1 (p=0.033). Conclusions: Latanoprost and dorzolamide/timolol fixed combination are effective treatments for newly diagnosed pseudoexfoliative glaucoma. In early-stage pseudoexfoliative glaucoma, greater intraocular pressure reduction was noted with dorzolamide/timolol fixed combination than with latanoprost; thus, dorzolamide/timolol fixed combination should be considered when a significant decrease in intraocular pressure is desired in early-stage glaucoma.
引用
收藏
页数:6
相关论文
共 29 条
  • [1] Major review: Exfoliation syndrome; advances in disease genetics, molecular biology, and epidemiology
    Aboobakar, Inas F.
    Johnson, William M.
    Stamer, W. Daniel
    Hauser, Michael A.
    Allingham, R. Rand
    [J]. EXPERIMENTAL EYE RESEARCH, 2017, 154 : 88 - 103
  • [2] 장세란, 2014, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V55, P854
  • [3] Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/ timolol maleate 0.5% fixed combination
    Akyol, Nurettin
    Kalkisim, Ahmet
    Turk, Adem
    Kola, Mehmet
    Imamoglu, Halil Ibrahim
    [J]. CUTANEOUS AND OCULAR TOXICOLOGY, 2017, 36 (04) : 397 - 403
  • [4] Optic nerve head parameters of high-definition optical coherence tomography and Heidelberg retina tomogram in perimetric and preperimetric glaucoma
    Begum, Viquar Unnisa
    Addepalli, Uday Kumar
    Senthil, Sirisha
    Garudadri, Chandra Sekhar
    Rao, Harsha Laxmana
    [J]. INDIAN JOURNAL OF OPHTHALMOLOGY, 2016, 64 (04) : 277 - 284
  • [5] Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
    Bell, Nicholas P.
    Ramos, Jose L.
    Feldman, Robert M.
    [J]. CLINICAL OPHTHALMOLOGY, 2010, 4 : 1331 - 1346
  • [6] A randomized trial comparing the dorzolamide-timolal combination given twice daily to monotherapy with timolol and dorzolamide
    Boyle, JE
    Ghosh, K
    Gieser, DK
    Adamsons, IA
    [J]. OPHTHALMOLOGY, 1998, 105 (10) : 1945 - 1951
  • [7] Latanoprost versus combined timolol and dorzolamide
    Bron, AM
    Emmerich, KH
    [J]. SURVEY OF OPHTHALMOLOGY, 2002, 47 : S148 - S154
  • [8] Management of advanced glaucoma: Characterization and monitoring
    de Moraes, C. Gustavo
    Liebmann, Jeffrey M.
    Medeiros, Felipe A.
    Weinreb, Robert N.
    [J]. SURVEY OF OPHTHALMOLOGY, 2016, 61 (05) : 597 - 615
  • [9] De Moraes CGV, 2011, ARCH OPHTHALMOL-CHIC, V129, P562, DOI 10.1001/archophthalmol.2011.72
  • [10] Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: Combined analysis of pooled data from two large randomized observer and patient-masked studies
    Fechtner, RD
    McCarroll, KA
    Lines, CR
    Adamsons, IA
    [J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 21 (03) : 242 - 249